China NT Pharma Calls EGM to Approve Major Acquisition and Share Issuance

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge-fund level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn announcement from China NT Pharma Group Co., Ltd. ( (HK:1011) ) is now available. China NT Pharma Group has convened an extraordinary general meeting for 15 January 2026 in Hong Kong to seek shareholder approval for the acquisition of 100% of the issued shares in three target companies—Junbinxiongdi Limited, Yuehua Limited and Zhong He Qun Lian Limited—under a sale and purchase agreement signed on 28 April 2025. The board is asking shareholders to ratify the agreement, approve the issuance and allotment of up to 274,751,679 new consideration shares at HK$0.45 each under a specific mandate to pay the sellers, and authorise directors to implement and, if necessary, amend the transaction once the Stock Exchange grants listing approval for the new shares, a move that would expand the group’s asset base while diluting existing holdings but potentially strengthening its strategic positioning in the market. The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page. More about China NT Pharma Group Co., Ltd. China NT Pharma Group Company Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange, operating as a pharmaceutical group. The company focuses on healthcare-related businesses in Greater China and manages its operations and corporate actions from its principal place of business and headquarters in Hong Kong. Average Trading Volume: 484,443 Technical Sentiment Signal: Buy Current Market Cap: HK$559.6M